This study discusses how restricting carbohydrates can reverse and prevent the metabolic syndrome.

Model performance had 45 percent sensitivity, 97 percent specificity, 77.4 percent overall accuracy

Excess risk has not improved over time and may be increasing for certain infections in young adults

It has been a dozen years since Dr. Steven Nissen took direct aim at pioglitazone and rosiglitazone, based on his interpretation of cardiac risk factors. The FDA rushed to put severe restriction on their usage and finally in 2010 rosiglitazone, also known as Avandia, was withdrawn from the market. Pioglitazone …

Combination dual therapy reduces mortality by 50%.

Obesity and uncontrolled blood glucose have effects on asthma.

Regular lifestyle counseling can have positive long term clinical outcomes in patients with diabetes. 

Adjuvant cyclical pressure TWO2 therapy better than sham control therapy for chronic diabetic foot ulcers

It has been over 6 years since the FDA approved Invokana as the first SGLT-2 inhibitor for the treatment of diabetes. When it was introduced there was a cautious optimism based on the tremendous amount of press concerning the fear of urinary tract infections. Usage was slow at first but …

FDA has approved a new treatment for diabetic kidney disease, which affects one in three patients with type 2 diabetes.